Article
Urology & Nephrology
Hironari Hanaoka, Jun Kikuchi, Kazuoto Hiramoto, Shuntaro Saito, Yasushi Kondo, Yuko Kaneko
Summary: This study investigated the incidence and factors associated with the progression of chronic kidney disease (CKD) in patients with stable rheumatoid arthritis (RA). The results showed that controlling inflammation contributes to inhibiting CKD progression in RA patients.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Rheumatology
Sizheng Steven Zhao, Lianne Kearlsey-Fleet, Ailsa Bosworth, Kath Watson, Kimme L. Hyrich
Summary: This study aimed to investigate the treatment outcomes for rheumatoid arthritis patients undergoing repeated trials of biologic or targeted synthetic DMARDs (b/tsDMARDs). The results showed that many patients eventually benefited from multiple rounds of treatment. Further research is needed to improve treatment selection and prevent prolonged trial and error approaches in some patients.
Article
Orthopedics
Yi Ren, Qi Yang, Tim Luo, Jin Lin, Jin Jin, Wenwei Qian, Xisheng Weng, Bin Feng
Summary: The study found that perioperative treatment with glucocorticoids and DMARDs can improve clinical outcomes for RA patients undergoing TKA, leading to better function, larger range of motion, and reduced postoperative pain in the long term.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
(2021)
Article
Rheumatology
Ylenia Ingrasciotta, Yinzhu Jin, Saveria S. S. Foti, Joan E. E. Landon, Michele Tari, Francesco Mattace-Raso, Seoyoung C. C. Kim, Gianluca Trifiro
Summary: This study compared baseline characteristics, anti-inflammatory drug use, and DMARD use patterns among RA patients in Southern Italy and the United States. The findings showed that most RA patients, especially elderly patients, were treated with anti-inflammatory drugs and csDMARDs rather than bDMARDs/tsDMARDs during the first year post-diagnosis, highlighting the need for better management of barriers in the use of these agents.
CLINICAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Giovanni Adami, Angelo Fassio, Francesca Pistillo, Camilla Benini, Ombretta Viapiana, Maurizio Rossini, Davide Gatti
Summary: This study aimed to investigate the factors associated with radiological progression in rheumatoid arthritis (RA) patients treated with biological DMARDs (bDMARDs). The results showed that baseline erosive disease, higher disease activity during treatment, younger age, and monotherapy were independently associated with the development of bone erosions. Additionally, the study team developed a predictive model that accurately forecasted the occurrence of new erosions in patients receiving bDMARDs.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2023)
Review
Cardiac & Cardiovascular Systems
Yang Baoqi, Ma Dan, Zhao Xingxing, Zhu Xueqing, Wang Yajing, Xu Ke, Zhang Liyun
Summary: Rheumatoid arthritis (RA) is an autoimmune disease associated with multiple comorbidities, including cardiovascular disease, lung cancer, lymphoma, infection, and osteoporosis. Therapeutic drugs for RA can have both beneficial and harmful effects on cardiovascular events.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Hong Ki Min, Se Hee Kim, Hae-Rim Kim, Sang-Heon Lee
Summary: Targeting specific pathologic pro-inflammatory cytokines or related molecules with biologic disease-modifying anti-rheumatic drugs (bDMARDs), such as monoclonal antibodies, has shown excellent therapeutic effects in various forms of inflammatory arthritis. These bDMARDs can target different pro-inflammatory cytokines, including tumor necrosis factor-alpha, interleukin (IL)-17A, IL-6, and IL-23/12, and control the inflammatory response by targeting specific cell-surface molecules. The therapeutic efficacy and adverse events of bDMARDs vary among different types of inflammatory arthritis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Rheumatology
Akhil Sood, Mukaila A. Raji
Summary: Strict control of systemic inflammation in chronic rheumatological diseases appears to significantly lower the risk of cognitive impairment in elderly patients, with biologic DMARDs showing promising effects on cognitive function.
CLINICAL RHEUMATOLOGY
(2021)
Article
Multidisciplinary Sciences
Tamseela Mumtaz, Ayesha Tahir, Maham Almas Tariq, Muhammad Amir Iqbal
Summary: The comparative toxicity of methotrexate and leflunomide on multiple organs in rheumatoid arthritis patients was evaluated in this study. While methotrexate had more harmful effects on the heart, blood vessels, and kidneys, leflunomide posed a greater risk to the liver.
Review
Pharmacology & Pharmacy
Xin Chen, Chengcheng Lu, Yanwen Duan, Yong Huang
Summary: Sinomenine is a benzyltetrahydroisoquinoline-type alkaloid with potent anti-inflammatory and analgesic effects, used for over 25 years in China to treat rheumatoid arthritis. However, its commercial hydrochloride form has low oral bioavailability and allergic reactions, requiring pharmaceutical strategies to improve delivery efficiency and reduce side effects.
Review
Health Care Sciences & Services
Mariangela Manfredi, Lieve Van Hoovels, Maurizio Benucci, Riccardo De Luca, Carmela Coccia, Pamela Bernardini, Edda Russo, Amedeo Amedei, Serena Guiducci, Valentina Grossi, Xavier Bossuyt, Carlo Perricone, Maria Infantino
Summary: uPAR is a membrane-bound glycoprotein, and its bioactive form, suPAR, is primarily expressed on the surface of immunologically active cells. Higher levels of suPAR have been associated with disease severity, relapse, and mortality in various inflammatory diseases. This review summarizes the current literature on the potential role of suPAR as a biomarker in autoimmune rheumatic and non-rheumatic diseases.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Hematology
Takuya Harada, Hiromi Iwasaki, Tsuyoshi Muta, Shingo Urata, Aiko Sakamoto, Kentaro Kohno, Ken Takase, Tomoya Miyamura, Takuya Sawabe, Hideki Asaoku, Kensuke Oryoji, Tomoaki Fujisaki, Yasuo Mori, Goichi Yoshimoto, Masahiro Ayano, Hiroki Mitoma, Toshihiro Miyamoto, Hiroaki Niiro, Hidetaka Yamamoto, Yumi Oshiro, Hiroaki Miyoshi, Koichi Ohshima, Morishige Takeshita, Koichi Akashi, Koji Kato
Summary: The study evaluated the clinical outcomes of MTX-LPD patients and found that the pathological subtype of lymphoma could predict the clinical outcome. Patients with polymorphic-type LPD had better event-free survival compared to other subtypes. Use of TNF-alpha inhibitors was associated with higher non-relapse mortality in DLBCL patients, while RA patients previously treated with JAK inhibitors more commonly required chemotherapy, indicating disease aggressiveness.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Immunology
Ivan Arias de la Rosa, Alejandro Escudero-Contreras, Miriam Ruiz-Ponce, Cristobal Roman-Rodriguez, Carlos Perez-Sanchez, Maria del Carmen Abalos-Aguilera, Rafaela Ortega-Castro, Juan Alcaide, Mora Murri, Pilar Font, Jerusalem Calvo-Gutierrez, Maria Luque-Tevar, Alejandra Maria Patino-Trives, Rocio Guzman-Ruiz, Maria del Mar Malagon, Francisco Jose Tinahones, Eduardo Collantes-Estevez, Chary Lopez-Pedrera, Nuria Barbarroja
Summary: Obesity may not directly impact disease activity in rheumatoid arthritis patients, but the induction of arthritis can lead to transcriptomic changes in adipose tissue under obesity conditions. Treatment with hydroxychloroquine can reduce weight and insulin resistance, with beneficial metabolic effects in adipose tissue.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Anthony James Ocon, George Reed, Dimitrios A. Pappas, Jeffrey R. Curtis, Joel M. Kremer
Summary: The study found that initiating glucocorticoids in steroid-naive RA patients is associated with an increased risk of cardiovascular events, especially at daily doses of >= 5mg, cumulative doses exceeding 1100mg, and durations longer than 81 days. No increased risk was found at lower doses or shorter durations.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Giovanni Adami, Angelo Fassio, Maurizio Rossini, Davide Bertelle, Francesca Pistillo, Camilla Benini, Ombretta Viapiana, Davide Gatti
Summary: Reducing glucocorticoid doses in rheumatoid arthritis patients can effectively decrease the risk of disease flare-ups. However, choosing the right tapering strategy remains challenging. The study found that tapering glucocorticoids to doses of 2.5 mg/day or below was associated with a higher risk of flare, suggesting the need for better tapering strategies to reduce the risk of recurrence in rheumatoid arthritis patients on biological disease-modifying antirheumatic drugs.